{
    "doi": "https://doi.org/10.1182/blood.V108.11.325.325",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=767",
    "start_url_page_num": 767,
    "is_scraped": "1",
    "article_title": "Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS. ",
    "article_date": "November 16, 2006",
    "session_type": "Oral Sessions",
    "abstract_text": "This is an update of the GITMO-IIL trial comparing R-HDS and CHOP-R in high-risk FL 1 47%. R-HDS has been already described (Ladetto et al ASH 2005). The CHOP-R arm consisted of CHOP and Rituximab delivered sequentially as already published (Rambaldi et al Blood 2002). Cross-over was allowed for pts failing CHOP-R. Centralized minimal residual disease (MRD) analysis with the bcl-2/IgH was planned on BM cells. Analysis was \u201cintention to treat\u201d. Toxic deaths were 4 (2 in each arm); in addition 1 gastric cancer and 2 MDS-ANLL occurred in the R-HDS arm and 1 head and neck cancer in the CHOP-R arm. CR rates were 59% with CHOP-R and 85% with R-HDS (p<0.001). Progressions were 28% with CHOP-R and 10% with R-HDS (p<0.025). At 36 months EFS and PFS for CHOP-R are 36% and 38% while for R-HDS are 66% and 72% (EFS: figure 1a). The better outcome for R-HDS was seen both in grade I, II and grade III pts. OS at 36 months was 83% in each arm. Cross-over from CHOP-R to R-HDS was chosen in 67% patients failing CHOP-R with a CR rate of 73%. MRD analysis is available in 44% of pts. A stable molecular remission (MR) was achieved in 26% of CHOP-R pts and 78% of R-HDS pts (p<0,001). A persistent MR was associated to an improved PFS (p<0,001) (figure 1b). Interestingly, PFS of PCR+ and PCR\u2212 pts was similar, regardless of the treatment received: 3-years PFS for PCR+ pts was 25% for CHOP-R and 32% for R-HDS, while 3-years PFS for PCR\u2212 pts was 67% with CHOP-R and 76% with R-HDS). This is the first randomized study with a significant proportion of molecularly-studied pts in FL and compares for the first time an intensified versus a conventional schedule in the Rituximab age. Conclusions are: a) R-HDS induces a greater number of CRs and ensures a better EFS and PFS compared to CHOP-R in this rare and aggressive population of pts. Indeed the good OS in both arms compared to historical controls suggests that current treatments are improving the outcome of these pts; b) R-HDS induces more MRs; c) the similar outcome observed in PCR+ and PCR\u2212 pts, regardless of the treatment received, indicates that the superior outcome of R-HDS compared to CHOP-R is largely explained by the superior rate of MRs achieved with the former treatment. View large Download slide Figure View large Download slide Figure ",
    "topics": [
        "chemotherapy regimen",
        "disease remission",
        "follicular lymphoma",
        "r-chop",
        "rituximab",
        "brachial plexus neuritis",
        "magnetic resonance spectroscopy",
        "melkersson-rosenthal syndrome",
        "craniosynostosis",
        "cyclophosphamide, doxorubicin, prednisone, and vincristine"
    ],
    "author_names": [
        "Marco Ladetto, MD",
        "Federica de Marco, MD",
        "Fabio Benedetti, MD",
        "Umberto Vitolo, MD",
        "Caterina Patti, MD",
        "Alessandro Rambaldi, MD",
        "Anna Marina Liberati, MD",
        "Maurizio Musso, MD",
        "Alessandro Pulsoni, MD",
        "Attilio Olivieri, MD",
        "Enzo Pavone, MD",
        "Enrico Pogliani, MD",
        "Delia Rota Scalabrini, MD",
        "Andrea Gallamini, MD",
        "Vincenzo Callea, MD",
        "Irene Ricca, MD",
        "Mario Boccadoro, MD",
        "Ignazio Majolino, MD",
        "Paolo Corradini, MD",
        "Alessandro M. Gianni, MD",
        "Corrado Tarella, MD"
    ],
    "author_affiliations": [
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ],
        [
            "on Behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy"
        ]
    ],
    "first_author_latitude": "19.9030921",
    "first_author_longitude": "-75.0966509"
}